IP Library › Granted Patent US 12,383,607
Granted Patent B2
US 12,383,607 · App. 18/818,363 · Granted Aug 12, 2025

Topical composition for improved healing of open wounds

Inventors: Mona E. Buice (Nicholson, GA); David M. Sailors (Athens, GA); Joshua Z Greeson (Brooklet, GA)
Assignee: Eleos Pharmaceuticals, Inc.
A61K38/28A61K9/0014A61K9/006A61K9/06A61K47/36A61P17/02A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,607
App. No.
18/818,363
Granted
Aug 12, 2025
Kind
B2
Abstract

The present disclosure is concerned with compositions comprising insulin and a pharmaceutically acceptable topical carrier. The present disclosure is also concerned with methods of using these compositions for the treatment of a skin ailment such as a diabetic ulcer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims (28)

1. A method of treating a diabetic foot ulcer in a human patient in need thereof, wherein the diabetic foot ulcer is refractory to systemic insulin the method comprising:

(a) determining that the patient has a glucose level of greater than 200 mg/dL at the site of the diabetic foot ulcer that is greater than the patient's systemic blood glucose level; and

(b) administering to the patient a pharmaceutical composition comprising insulin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is topically administered to the patient at the site of the diabetic foot ulcer.

2. A method of treating a diabetic foot ulcer in a human patient in need thereof that has been determined to have a glucose level of greater than 200 mg/dL at the site of the diabetic foot ulcer that is greater than the patient's systemic blood glucose level wherein the diabetic foot ulcer is refractory to systemic insulin, the method comprising administering to the patient a pharmaceutical composition comprising insulin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is topically administered to the patient at the site of the diabetic foot ulcer.

3. The method of claim 1 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 250 mg/dL.

4. The method of claim 3 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 300 mg/dL.

5. The method of claim 4 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 350 mg/dL.

6. The method of claim 5 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 400 mg/dL.

7. The method of claim 6 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 450 mg/dL.

8. The method of claim 7 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 500 mg/dL.

9. The method of claim 8 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 550 mg/dL.

10. The method of claim 9 , wherein the patient is determined to have a glucose level at the site of the diabetic foot ulcer of greater than 600 mg/dL.

11. The method of claim 1 , wherein the pharmaceutical composition is a gel, aerosol, cream, ointment, lotion, dusting powder, or jelly.

12. The method of claim 1 , wherein the insulin is rapid-acting, short-acting, intermediate-acting, or long-acting.

13. The method of claim 12 , wherein the rapid-acting insulin is insulin glulisine, insulin lispro, or insulin aspart.

14. The method of claim 12 , wherein the long-acting insulin is insulin detemir or insulin glargine.

15. The method of claim 2 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 250 mg/dL.

16. The method of claim 15 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 300 mg/dL.

17. The method of claim 16 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 350 mg/dL.

18. The method of claim 17 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 400 mg/dL.

19. The method of claim 18 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 450 mg/dL.

20. The method of claim 19 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 500 mg/dL.

21. The method of claim 20 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 550 mg/dL.

22. The method of claim 21 , wherein the patient has been determined to have a glucose level at the site of the diabetic foot ulcer of greater than 600 mg/dL.

23. The method of claim 2 , wherein the pharmaceutical composition is a gel, aerosol, cream, ointment, lotion, dusting powder, or jelly.

24. The method of claim 2 , wherein the insulin is rapid-acting, short-acting, intermediate-acting, or long-acting.

25. The method of claim 24 , wherein the rapid-acting insulin is insulin glulisine, insulin lispro, or insulin aspart.

26. The method of claim 24 , wherein the long-acting insulin is insulin detemir or insulin glargine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: BUICE, MONA E.; SAILORS, DAVID M.; GREESON, JOSHUA Z.
To: ELEOS PHARMACEUTICALS, LLC
Reel/Frame 070491/0141 →
CHANGE OF NAME Recorded Mar 12, 2025
From: ELEOS PHARMACEUTICALS, LLC
To: ELEOS PHARMACEUTICALS, INC.
Reel/Frame 070494/0517 →
Continuity (5)
Continuation 18056981 · Nov 18, 2022
Continuation 16165502 · Oct 19, 2018
Provisional Application 62678574 · May 31, 2018
Provisional Application 62574481 · Oct 19, 2017
Related Publication 20250025534A1 · Jan 23, 2025
References Cited (80)
US 6155992A · Henning et al. · 2000 [cited by applicant]
US 8093211B2 · Tennenbaum et al. · 2012 [cited by applicant]
US 9993425B2 · Costantino et al. · 2018 [cited by applicant]
US 11369664B2 · Buice et al. · 2022 [cited by applicant]
US 20060009373A1 · Martin · 2006 [cited by applicant]
US 20110294730A1 · Shantha et al. · 2011 [cited by applicant]
US 20120003296A1 · Shantha et al. · 2012 [cited by applicant]
US 20140038911A1 · Eickelmann et al. · 2014 [cited by applicant]
US 20150094260A1 · Braiman-Wiksman et al. · 2015 [cited by applicant]
US 20150150919A1 · Alves Mendes · 2015 [cited by examiner]
US 20150250856A1 · Schwarz et al. · 2015 [cited by applicant]
US 20160045158A1 · Hsu · 2016 [cited by examiner]
US 20160051683A1 · Banov · 2016 [cited by applicant]
US 20160220581A1 · Komorowski et al. · 2016 [cited by applicant]
US 20170008945A1 · Madsen et al. · 2017 [cited by applicant]
US 20190290736A1 · Buice et al. · 2019 [cited by applicant]
US 20210162015A1 · Buice et al. · 2021 [cited by applicant]
CN 103566359A · 2014 [cited by applicant]
RU 2203500C2 · 2003 [cited by applicant]
WO WO2010097800A1 · 2010 [cited by applicant]
WO WO2012135422A2 · 2012 [cited by applicant]
WO WO2014145484A2 · 2014 [cited by examiner]
WO WO2019079710A1 · 2019 [cited by applicant]
William, “Diabetes and Wounds: Love the Skin You're in”, Voice of the Diabetic, vol. 24, No. 1, Winter 2009, pp. 1-3 (Year: 2009). [cited by examiner]
“Novolog (RXList),” dated Jul. 14, 2017, retrieved from <https://web.archive.org/web/20170714054151/https://www.rxlist.com/novolog-drug.htm> (53 pages). [cited by applicant]
Yazdanpanah et al., “Literature review on the management of diabetic foot ulcer,” World J Diabetes. 6(1):37-53 (2015) (18 pages). [cited by applicant]
Huijberts et al., “Advanced glycation end products and diabetic foot disease,” Diabetes Metab Res Rev. 24(S1): S19-S24 (Abstract Only) (Apr. 2008) (3 pages). [cited by applicant]
Singh et al., “Advanced Glycation End Products and Diabetic Complications,” Korean J Physiol Pharmacol. 18: 1-14 (Feb. 2014). [cited by applicant]
Extended European Seach Report for European Patent Application No. 20759637.0, dated Sep. 30, 2022 (7 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/018808, mailed May 27, 2020 (15 pages). [cited by applicant]
Ramarao et al., “Comparative Study between the Effect of Topical Insulin and Normal Saline Dressing in Healing of Diabetic Foot Ulcers,” International Journal of Contemporary Medical Research. 4(6): 1337-1339 (Jun. 2017… [cited by applicant]
Stephen et al., “A Randomized, Controlled Trial to Assess the Effect of Topical Insulin Versus Normal Saline in Pressure Ulcer Healing,” Ostomy Wound Manage. 62(6):16-23 (2016) (6 pages). [cited by applicant]
Liu et al., “Insulin regulates multiple signaling pathways leading to monocyte/macrophage chemotaxis into the wound tissue,” Biol Open. 7(1):bio026187 (Jan. 2018) (11 pages). [cited by applicant]
Oryan et al., “Effects of insulin on wound healing: a review of animal and human evidences,” Life Sci. 174:59-67 (Apr. 2017) (9 pages). [cited by applicant]
Kakanj et al., “Insulin and TOR signal in parallel through FOXO and S6K to promote epithelial wound healing,” Nat Commun. 7:12972 (2016) (16 pages). [cited by applicant]
Azevedo et al., “Effect of Topical Insulin on Second-Degree Burns in Diabetic Rats,” Biol Res Nurs. 18(2):181-92 (2015) (12 pages). [cited by applicant]
Apikoglu-Rabus et al., “Effect of topical insulin on cutaneous wound healing in rats with or without acute diabetes,” Clin Exp Dermatol. 35(2):180-5 (2009) (6 pages). [cited by applicant]
“PCCA MucoloxTM,” <https://horstpharmacy.com/wp-content/uploads/2018/05/98891_MucoLoxSpecSheet_PRACT.pdf>, retrieved Jun. 25, 2020 (2010) (3 pages). [cited by applicant]
Abdelkader et al., “Enhanced cutaneous wound healing in rats following topical delivery of insulin-loaded nanoparticles embedded in poly(vinyl alcohol)-borate hydrogels,” Drug Deliv Transl Res. 8(5):1053-1065 (Oct. 2018… [cited by applicant]
Wang et al., “Effects of topical insulin on wound healing: a review of animal and human evidences,” Diabetes Metab Syndr Obes. 13:719-27 (2020) (9 pages). [cited by applicant]
Nie et al., “Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis,” Cell Transplant. 20(2):205-16 (2011). [cited by applicant]
PCCA Science, Technical Report: Assessment of the Mucoadhesive Properties of MucoloxTM Using a 3D Model of the Human Oral Mucosa. 2015. [cited by applicant]
Blakytny et al., “The Molecular Biology of Chronic Wounds and Delayed Healing in Diabetes,” Diabet Med. 23(6):594-608 (2006). [cited by applicant]
Barrientos et al., “Clinical application of growth factors and cytokines in wound healing,” available in PMC Mar. 30, 2016, published in final edited form as: Wound Repair Regen. 22(5):569-78 (2014) (18 pages). [cited by applicant]
Sen et al., “Human skin wounds: a major and snowballing threat to public health and the economy,” available in PMC Nov. 1, 2010, published in final edited form as: Wound Repair Regen. 17(6):763-71 (2009) (14 pages). [cited by applicant]
Armstrong et al., “Mind the Gap: Disparity Between Research Funding and Costs of Care for Diabetic Foot Ulcers,” Diabetes Care. 36(7):1815-7 (2013). [cited by applicant]
Hrynyk et al., “Alginate-PEG sponge architecture and role in the design of insulin release dressings,” Biomacromolecules. 13(5):1478-85 (2012). [cited by applicant]
Baquerizo Nole et al., “Wound Research Funding from Alternative Sources of Federal Funds in 2012,” Wound Repair Regen. 22(3):295-300 (2014). [cited by applicant]
Goenka et al., “Role of topical use of insulin in healing of chronic ulcer,” Med J Dy Patil Univ 7(5):579-83 (2014) (5 pages). [cited by applicant]
Boulton et al., “The Global Burden of Diabetic Foot Disease. Lancet,” 366(9498):1719-24 (2005). [cited by applicant]
Zhao et al., “pH and Glucose Dual-Responsive Injectable Hydrogels with Insulin and Fibroblasts as Bioactive Dressings for Diabetic Wound Healing,” ACS Appl Mater Interfaces. 9(43):37563-37574 (Nov. 2017). [cited by applicant]
“MUCOLOXTM (30-4782),” <https://www.pccarx.com/products/PCCAMUCOLOX%E2%84%A2/30-4782/PROPRIETARYBASES>, retrieved on Aug. 2, 2021 (2 pages). [cited by applicant]
Mekkes et al., “Causes, Investigation and Treatment of Leg Ulceration,” Br J Dermtol. 148(3):388-401 (2003). [cited by applicant]
Ding et al., “Multilayered mucoadhesive hydrogel films based on thiolated hyaluronic acid and polyvinylalcohol for insulin delivery,” Acta Biomater. 8(10):3643-51 (2012). [cited by applicant]
Liao et al., “Hyaluronan: Pharmaceutical Characterization and Drug Delivery,” Drug Deliv. 12(6):327-42 (2005). [cited by applicant]
Cruz-Cazarim et al., “Prospective insulin-based ophthalmic delivery systems for the treatment of dry eye syndrome and corneal injuries,” Eur J Pharm Biopharm. 140:1-10 (2019) (10 pages). [cited by applicant]
Zhang et al., “Effect of local insulin injection on wound vascularization in patients with diabetic foot ulcer,” Exp Ther Med. 11(2):397-402 (2016). [cited by applicant]
International Search Report and Written Opinion mailed on Dec. 20, 2018 by the International Searching Authority for Patent Application No. PCT/US2018/056697, which was filed on Oct. 19, 2018 and published as WO 2019/07… [cited by applicant]
Martínez-Jiménez et al., “Effects of Local Use of Insulin on Wound Healing in Non-diabetic Patients,” Plast Surg (Oakv). 26(2):75-79 (May 2018). [cited by applicant]
Liu et al., “Cell and molecular mechanisms of insulin-induced angiogenesis,” J Cell Mol Med. 13(11-12):4492-504 (2009). [cited by applicant]
Lima et al., “Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: a double-blind placebo-controlled clinical trial,” PLoS One. 7(5):e36974 (2012) (13 pages). [cited by applicant]
Blair et al., “Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs,” J Control Release. 91(3):385-394 (2003). [cited by applicant]
Moura et al., “Recent Advances on the Development of Wound Dressings for Diabetic Foot Ulcer Treatment—A Review,” Acta Biomaterialia. 9:7093-14 (2013). [cited by applicant]
Martínez-Jiménez et al., “Local use of insulin in wounds of diabetic patients: higher temperature, fibrosis, and angiogenesis,” Plast Reconstr Surg. 132(6):1015e-1019e (2013) (7 pages). [cited by applicant]
Pakyari et al., “Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing,” Adv Wound Care (New Rochelle). 2(5):215-224 (2013). [cited by applicant]
Zagon et al., “Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus,” Arch Ophthalmol. 125(8):1082-8 (2007). [cited by applicant]
Rafehi et al., “Genetic and Epigenetic Events in Diabetic Wound Healing,” Int Wound J. 8(1):12-21 (2011). [cited by applicant]
Negrini et al., “Effects of topical insulin on second-intention wound healing in the red-eared slider turtle ( [cited by applicant]
Su et al., “Chemokine Regulation of Neutrophil Infiltration of Skin Wounds,” Adv Wound Care (New Rochelle). 4(11):631-640 (2015). [cited by applicant]
Sreenivas et al., “Thiolated Chitosans: Novel Polymers for Lucoadhesive Drug Delivery—A Review,” Trop J Pharm Res. 7(3):1077-88 (2008). [cited by applicant]
Armstrong et al., “Diabetic Foot Ulcers and Vascular Insufficiency: Our Population Has Changed, but Out Methods Have Not,” J Diabetes Sci Technol. 5(6):1591-5 (2011). [cited by applicant]
Loots et al., “Differences in Cellular Infiltrate and Extracellular Matrix of Chronic Diabetic and Venous Ulcers Versus Acute Wounds,” J Invest Dermatol. 111 (5):850-7 (1998). [cited by applicant]
Preedy et al., “Novel coatings in biotechnology trends in inhaler devices,” Inhaler Devices: Fundamentals, Design and Drug Delivery, Woodhead Publishing Limited, 37-50 (2013). [cited by applicant]
Dawoud et al., “Insulin mucoadhesive liposomal gel for wound healing: a formulation with sustained release and extended stability using quality by design approach,” AAPS PharmSciTech. 20(4):158 (2019) (15 pages). [cited by applicant]
Yu et al., “Topical insulin accelerates cutaneous wound healing in insulin-resistant diabetic rats,” Am J Transl Res. 9(10):4682-4693. [cited by applicant]
Extended European Search Report for European Patent Application No. 18868249.6, mailed Jun. 21, 2021 (8 pages). [cited by applicant]
Vatankhah et al., “Effect of systemic insulin treatment on diabetic wound healing,” available in PMC Apr. 1, 2018, published in final edited form as: Wound Repair Regen. 25(2):288-291 (Apr. 2017) (9 pages). [cited by applicant]
Rayment et al., “Increased Matrix Metalloproteinase-9 (MMP-9) Activity Observed in Chorinc Wound Fluid is Related to the Clinical Severity of the Ulcer,” Br J Dermatol. 158(5):951-61 (2008). [cited by applicant]
Cole-King et al., “Psychological Factors and Delayed Healing in Chronic Wounds,” Psychosom Med. 63(2):216-20 (2001). [cited by applicant]
Liu et al., “Increased Matrix Metalloproteinase-9 Predicts Poor Wound Healing in Diabetic Foot Ulcers,” Diabetes Care. 32(2):117-9 (2009). [cited by applicant]